Published in J Neuroinflammation on December 07, 2010
A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol (2014) 1.83
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol (2012) 1.62
Development of antihuman IgG antibodies and hematologic deficits but not clinical abnormalities in C57BL/6 mice after repeated administration of human intravenous immunoglobulin. Comp Med (2012) 1.61
Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered? J Neuroinflammation (2014) 1.41
Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound. Exp Neurol (2013) 1.19
Animal models in the drug discovery pipeline for Alzheimer's disease. Br J Pharmacol (2011) 1.13
Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies. Pharmacol Ther (2013) 1.06
Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier. J Cereb Blood Flow Metab (2013) 1.01
Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease. J Neuroinflammation (2012) 0.99
Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers Aβ in APP/PS1 mice along a different time course than anti-Aβ antibodies. J Neurosci (2013) 0.97
Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis. J Neuroinflammation (2011) 0.96
Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease. Int J Alzheimers Dis (2012) 0.93
Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target. J Clin Immunol (2014) 0.93
Herpes Simplex Virus Type 1 and Other Pathogens are Key Causative Factors in Sporadic Alzheimer's Disease. J Alzheimers Dis (2015) 0.91
Intravenous immunoglobulin protects neurons against amyloid beta-peptide toxicity and ischemic stroke by attenuating multiple cell death pathways. J Neurochem (2012) 0.89
Utilization of APPswe/PS1dE9 Transgenic Mice in Research of Alzheimer's Disease: Focus on Gene Therapy and Cell-Based Therapy Applications. Int J Alzheimers Dis (2011) 0.86
Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes. Neurol Neuroimmunol Neuroinflamm (2016) 0.84
Intravenous immunoglobulin and Alzheimer's disease: what now? J Neuroinflammation (2013) 0.83
Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients. PLoS One (2013) 0.82
An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloid-beta: the dust-raising effect. J Neuroinflammation (2015) 0.82
Beta-amyloid auto-antibodies are reduced in Alzheimer's disease. J Neuroimmunol (2014) 0.82
Mechanisms of action of naturally occurring antibodies against β-amyloid on microglia. J Neuroinflammation (2013) 0.81
Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease. J Neuroinflammation (2012) 0.80
Immunomodulation and AD--down but not out. J Clin Immunol (2014) 0.80
Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease. J Clin Immunol (2014) 0.79
Susceptibility to focal and global brain ischemia of Alzheimer mice displaying aβ deposits: effect of immunoglobulin. Aging Dis (2014) 0.78
Animal Models of Alzheimer's Disease: Utilization of Transgenic Alzheimer's Disease Models in Studies of Amyloid Beta Clearance. Curr Transl Geriatr Exp Gerontol Rep (2012) 0.78
Intravenous immunglobulin binds beta amyloid and modifies its aggregation, neurotoxicity and microglial phagocytosis in vitro. PLoS One (2013) 0.77
Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide. PLoS One (2012) 0.77
Immunological evidence and regulatory potential for cell-penetrating antibodies in intravenous immunoglobulin. Clin Transl Immunology (2015) 0.77
Protective effect of 14-3-3 antibodies on stressed neuroretinal cells via the mitochondrial apoptosis pathway. BMC Ophthalmol (2015) 0.76
IgG Conformer's Binding to Amyloidogenic Aggregates. PLoS One (2015) 0.75
Aβ and Inflammatory Stimulus Activate Diverse Signaling Pathways in Monocytic Cells: Implications in Retaining Phagocytosis in Aβ-Laden Environment. Front Cell Neurosci (2016) 0.75
Disease-modifying effect of intravenous immunoglobulin in an experimental model of epilepsy. Sci Rep (2017) 0.75
A human monoclonal IgG that binds aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo. J Neurosci (2015) 0.75
Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 19.36
Alzheimer's disease: genes, proteins, and therapy. Physiol Rev (2001) 19.19
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science (2005) 14.43
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurosci Res (1993) 9.81
Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci (2004) 9.73
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89
Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci (1993) 7.92
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem (1991) 7.04
Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature (2008) 6.89
A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2001) 6.78
Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med (2006) 6.15
Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet (2003) 5.92
Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med (2007) 5.87
Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem (2002) 5.63
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 5.60
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01
Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med (2003) 4.77
Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A (2008) 3.55
Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol (2008) 3.05
Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science (2002) 2.78
Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med (2004) 2.72
Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci (2008) 2.57
Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci (2003) 2.44
Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci (2002) 2.44
Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci (2004) 2.38
Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol (2006) 2.25
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging (2008) 2.24
Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci U S A (1996) 1.87
Neuroprotective role of the innate immune system by microglia. Neuroscience (2007) 1.83
Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia (2002) 1.79
Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis (2004) 1.73
IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci (2005) 1.69
Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol (2002) 1.68
Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden. Ann Neurol (2009) 1.65
Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations. Int Immunopharmacol (2009) 1.65
Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides (2002) 1.64
Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. Mol Biol Cell (2007) 1.61
Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology (2001) 1.58
The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol Aging (2004) 1.56
Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci U S A (2007) 1.46
Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J Biol Chem (1997) 1.43
Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 1.39
Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol (2002) 1.29
Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden. J Neurosci (2007) 1.28
Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's disease. J Alzheimers Dis (2007) 1.28
Beta-amyloid stimulates murine postnatal and adult microglia cultures in a unique manner. J Neurosci (2006) 1.24
Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain (2003) 1.24
Natural human antibodies to amyloid beta peptide. Autoimmun Rev (2008) 1.20
In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. J Neurochem (2007) 1.19
Degradation of fibrillar forms of Alzheimer's amyloid beta-peptide by macrophages. Neurobiol Aging (2007) 1.17
Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. Mol Cell Neurosci (2008) 1.11
IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology (2009) 1.08
Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. J Biol Chem (2005) 1.04
Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. J Neurosci Res (2006) 1.01
Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J Immunol (2006) 0.98
The microglia-activating potential of thrombin: the protease is not involved in the induction of proinflammatory cytokines and chemokines. J Biol Chem (2004) 0.97
Proteolytic degradation of Alzheimer's disease amyloid beta-peptide by a metalloproteinase from microglia cells. J Neurochem (1998) 0.94
beta-Amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or beta-amyloid deposits. Proc Natl Acad Sci U S A (2006) 0.94
Induction of matrix metalloproteinases (MMP3, MMP12 and MMP13) expression in the microglia by amyloid-beta stimulation via the PI3K/Akt pathway. Exp Gerontol (2007) 0.92
Triple fluorescence labelling of neuronal, glial and vascular markers revealing pathological alterations in various animal models. J Chem Neuroanat (2008) 0.90
Intravenous immunoglobulin reduces infarct volume but not edema formation in acute stroke. Neuroimmunomodulation (2009) 0.87
Comparison of intravenous immunoglobulins for naturally occurring autoantibodies against amyloid-beta. J Alzheimers Dis (2010) 0.86
Antibodies to beta-amyloid decrease the blood-to-brain transfer of beta-amyloid peptide. Exp Biol Med (Maywood) (2002) 0.86
Immune complexes of auto-antibodies against A beta 1-42 peptides patrol cerebrospinal fluid of non-Alzheimer's patients. Mol Psychiatry (2007) 0.83
Polyclonal immunoglobulins (IVIg) induce expression of MMP-9 in microglia. J Neuroimmunol (2009) 0.79
Müller cells in the healthy and diseased retina. Prog Retin Eye Res (2006) 5.07
Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci (2009) 2.33
Improving outcome after stroke: overcoming the translational roadblock. Cerebrovasc Dis (2008) 2.26
Neurocognitive aging: prior memories hinder new hippocampal encoding. Trends Neurosci (2006) 2.20
Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol Dis (2005) 2.16
Age-associated alterations of hippocampal place cells are subregion specific. J Neurosci (2005) 1.82
Peeling of the basal membrane in the human retina: ultrastructural effects. Ophthalmology (2004) 1.80
Stroke research priorities for the next decade--A representative view of the European scientific community. Cerebrovasc Dis (2006) 1.75
Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210. FEBS Lett (2008) 1.75
Increased fMRI responses during encoding in mild cognitive impairment. Neurobiol Aging (2006) 1.74
Role of alpha-synuclein in presynaptic dopamine recruitment. J Neurosci (2004) 1.74
Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease. Brain (2002) 1.71
Visual presentation of novel objects and new spatial arrangements of objects differentially activates the medial temporal lobe subareas in humans. Eur J Neurosci (2004) 1.63
Role of retinal glial cells in neurotransmitter uptake and metabolism. Neurochem Int (2008) 1.59
Nuclear factor-kappaB contributes to infarction after permanent focal ischemia. Stroke (2004) 1.58
Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals. J Neurosci (2003) 1.58
Activity-dependent formation and functions of chondroitin sulfate-rich extracellular matrix of perineuronal nets. Dev Neurobiol (2007) 1.56
Dietary energy substrates reverse early neuronal hyperactivity in a mouse model of Alzheimer's disease. J Neurochem (2013) 1.51
Protein disulfide isomerase in ALS mouse glia links protein misfolding with NADPH oxidase-catalyzed superoxide production. Hum Mol Genet (2012) 1.49
Role of p38 and p44/42 mitogen-activated protein kinases in microglia. Glia (2002) 1.49
Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiol Dis (2003) 1.48
Muller cells are living optical fibers in the vertebrate retina. Proc Natl Acad Sci U S A (2007) 1.48
Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol (2011) 1.41
Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 1.38
Rho mediates calcium-dependent activation of p38alpha and subsequent excitotoxic cell death. Nat Neurosci (2007) 1.36
Orexin loss in Huntington's disease. Hum Mol Genet (2004) 1.33
Nrf2 regulates antioxidant gene expression evoked by oxidized phospholipids in endothelial cells and murine arteries in vivo. Circ Res (2008) 1.32
Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 1.31
Stable RNA interference: comparison of U6 and H1 promoters in endothelial cells and in mouse brain. J Gene Med (2006) 1.29
Flexible polyimide microelectrode array for in vivo recordings and current source density analysis. Biosens Bioelectron (2006) 1.28
Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden. J Neurosci (2007) 1.28
Targeted inactivation of dystrophin gene product Dp71: phenotypic impact in mouse retina. Hum Mol Genet (2003) 1.27
Interactions between Alzheimer's disease and cerebral ischemia--focus on inflammation. Brain Res Brain Res Rev (2005) 1.26
Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease. Glia (2008) 1.23
P2X7 receptor expression after ischemia in the cerebral cortex of rats. J Neuropathol Exp Neurol (2004) 1.21
Blood-brain barrier breakdown after embolic stroke in rats occurs without ultrastructural evidence for disrupting tight junctions. PLoS One (2013) 1.20
Endocannabinoid-independent retrograde signaling at inhibitory synapses in layer 2/3 of neocortex: involvement of vesicular glutamate transporter 3. J Neurosci (2004) 1.18
Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. J Pharmacol Exp Ther (2004) 1.17
Longitudinal observation on CSF Abeta42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice. Neurobiol Dis (2004) 1.17
Cognitive aging and the hippocampus: how old rats represent new environments. J Neurosci (2004) 1.17
Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors. Eur J Neurosci (2006) 1.15
Expression of interleukin-18 is increased in the brains of Alzheimer's disease patients. Neurobiol Aging (2007) 1.15
Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol Dis (2005) 1.15
Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. J Cereb Blood Flow Metab (2005) 1.14
Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology (Berl) (2005) 1.14
Unique luminal localization of VGAT-C terminus allows for selective labeling of active cortical GABAergic synapses. J Neurosci (2008) 1.14
Permanent middle cerebral artery occlusion in sheep: a novel large animal model of focal cerebral ischemia. J Cereb Blood Flow Metab (2008) 1.12
Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. Mol Cell Neurosci (2008) 1.11
Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain (2011) 1.10
Pyrrolidine dithiocarbamate inhibits translocation of nuclear factor kappa-B in neurons and protects against brain ischaemia with a wide therapeutic time window. J Neurochem (2004) 1.10
Encoding of novel picture pairs activates the perirhinal cortex: an fMRI study. Hippocampus (2003) 1.10
Hypothermia in mice tested in Morris water maze. Behav Brain Res (2003) 1.09
Regeneration of myenteric plexus in the mouse colon after experimental denervation with benzalkonium chloride. J Comp Neurol (2003) 1.08
Perioculomotor cell groups in monkey and man defined by their histochemical and functional properties: reappraisal of the Edinger-Westphal nucleus. J Comp Neurol (2008) 1.08
Regulation of microglial inflammatory response by histone deacetylase inhibitors. J Neurochem (2003) 1.08
Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. J Neurosci Res (2010) 1.08
WNT signaling in activated microglia is proinflammatory. Glia (2010) 1.07
A novel quantification of blood-brain barrier damage and histochemical typing after embolic stroke in rats. Brain Res (2010) 1.07
Cognition-enhancing and anxiolytic effects of memantine. Neuropharmacology (2008) 1.06
Complementary distribution of type 1 cannabinoid receptors and vesicular glutamate transporter 3 in basal forebrain suggests input-specific retrograde signalling by cholinergic neurons. Eur J Neurosci (2003) 1.06
Deleterious role of superoxide dismutase in the mitochondrial intermembrane space. J Biol Chem (2008) 1.06
Brain-derived neurotrophic factor controls functional differentiation and microcircuit formation of selectively isolated fast-spiking GABAergic interneurons. Eur J Neurosci (2004) 1.05
The role and therapeutic potential of monocytic cells in Alzheimer's disease. Glia (2010) 1.04
Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. Proc Natl Acad Sci U S A (2002) 1.04
Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A. Neurobiol Dis (2008) 1.03
Role of alpha-synuclein in synaptic glutamate release. Neurobiol Dis (2007) 1.02
Region and lamina-specific distribution of extracellular matrix proteoglycans, hyaluronan and tenascin-R in the mouse hippocampal formation. J Chem Neuroanat (2003) 1.02
ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells. J Invest Dermatol (2008) 1.02
Individual differences in neurocognitive aging of the medial temporal lobe. Age (Dordr) (2006) 1.01
Fate of extrahepatic human stem and precursor cells after transplantation into mouse livers. Hepatology (2007) 1.01
Impaired TrkB receptor signaling contributes to memory impairment in APP/PS1 mice. Neurobiol Aging (2011) 1.01
Cracking down on inhibition: selective removal of GABAergic interneurons from hippocampal networks. J Neurosci (2012) 1.00
Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease. J Neuroinflammation (2012) 0.99